We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.
- Authors
MacFarlane, M; Inoue, S; Kohlhaas, S L; Majid, A; Harper, N; Kennedy, D B J; Dyer, M J S; Cohen, G M
- Abstract
Clinical trials have been initiated with Apo2L/TRAIL (Genentech) and agonistic mAbs to TRAIL receptors, -R1 and -R2 (Human Genome Sciences). The apoptosis-inducing ability of these mAbs and different TRAIL preparations, in the presence or absence of histone deacetylase inhibitors (HDACi), varied markedly against primary chronic lymphocytic leukaemia (CLL) cells and various tumor cell lines, demonstrating an unanticipated preferential apoptotic signaling via either TRAIL-R1 or -R2. Contrary to literature reports that TRAIL-induced apoptosis occurs primarily via signaling through TRAIL-R2, CLL cells, in the presence of HDACi, undergo predominantly TRAIL-R1-mediated apoptosis. Consequently, Apo2L/TRAIL, which signals primarily through TRAIL-R2, is virtually devoid of activity against CLL cells. To maximize therapeutic benefit, it is essential to ascertain whether a primary tumor signals via TRAIL-R1/-R2, prior to initiating therapy. Thus combination of an agonistic TRAIL-R1 Ab and an HDACi, such as the anticonvulsant sodium valproate, could be of value in treating CLL.
- Publication
Cell death and differentiation, 2005, Vol 12, Issue 7, p773
- ISSN
1350-9047
- Publication type
Journal Article
- DOI
10.1038/sj.cdd.4401649